Research and development of protective vaccines and other countermeasures against infectious disease agents of military importance award

Active Cooperative Agreement Awarded Last action

Award ID
N626451920002
Recipient
Awarding agency
Obligated
$82,338,342

Award facts

Assistance listing
12.340 Naval Medical Research and Development
Completion date 72% complete
Originally
Place of performance
Westlake, MD 20817, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment As a result of this modification, the total obligated amount was not changed. $0
Amendment Funding and appointment of alternate grants officer representative $2,676,474
Amendment $1,675,135
Amendment $377,676
Amendment Incremental funding $2,076,907
Amendment Incremental funding and adding approved protocols. $832,891
Amendment $805,788
Amendment Incremental funding and approved protocols $90,500
Amendment $109,716
Amendment Incremental funding $1,011,796
Amendment Deobligation of expired funds. -$772,741
Amendment $1,372,266
Amendment Incremental funding $354,700
Amendment Adding approved protocols $0
Amendment Correction modification $0
Amendment $124,000
Amendment $1,169,963
Amendment $175,000
Amendment Incremental funding $1,005,137
Amendment $0
Amendment Incremental funding - research and development of protective vaccines and other countermeasures against infectious disease agents of military importance $46,951
Amendment Incremental funding $185,310
Amendment Add clins, revise terms and conditions. $0
Amendment $6,841,113
Amendment $563,948
Amendment $90,000
Amendment Incremental funding $115,431
Amendment Additional funding and incorporation of previously approved protocols and sub-awards. $650,000
Amendment Additional funding only $106,033
Amendment As a result of this modification, the total funded amount for this document was increased by $5,203,603.87 from $55,450,742.69 to $60,654,346.56. $5,203,604
Amendment This modification incorporates sub-award prior approval and increases incremental funding. $250,000
Amendment This modification increases the budget to accommodate for unanticipated covid-19 infectious disease research. $0
Amendment This modification issues a one-time 12-month no cost extension, increases incremental funding and removes animal restriction for protocol 23-10-ORI $594,753
Amendment This modification adds incremental funding and corrects the line of accounting under slin 000246, new slin is 000310 $108,108
Amendment This modification adds incremental funding and tranfers costs to a new clin in order to accomodate additional lines of accounting $1,865,776
Amendment This modification adds prior approval for new contracts, adds funding, and adds approved protocol to the naval medical research center cooperative agreement $2,416,839
Amendment This modification provides prior approval for temporary HJF clinical trial center staff adds approved protocols and adds funding. $584,597
Amendment This modification provides prior approval for equipment. $0
Amendment This modification corrects the LOA used P00027. $0
Amendment This modification removes animal restrictions for protocol#: 22-27-ORI & protocol#: NLS-22-12-007. $0
Amendment This modification provides prior approval for a subaward, equipment, and personnel action. $0
Amendment This modification provides prior approval for a subaward. $0
Amendment This modification makes an administrative correction to P00038. $0
Amendment This modification removes animal use restrictions. $0
Amendment This modification provides prior approval for an equipment purchase. $0
Amendment $7,336,321
Amendment This modification adds incremental funding. $2,592,577
Amendment This modification changes the GOR, adds incremental funding, and removes animal use restrictions. $8,070,078
Amendment This modification provides prior approval for a subaward to centivax, INC. $0
Amendment This modification corrects MOD P00031. IT deobligates slins 000201-000207 and replaces them with slins 000208-000214. $0
Show 40 more

Latest 50 listed here. See the rest on GovTribe.

Subawards

Subrecipient Amount Awarded
Immuron LIMITED Supporting research and development of protective vaccines and other countermeasures against infectious disease agents of military importance. $451,000
University Of Vermont & State Agricultural College $34,677
Wake Forest University Health Sciences Research conducting a ferret study following CDC-DHHS protocol to generate immune serum to flu viruses $121,990
Antagen Biosciences Inc. INTRODUCTION/BACKGROUND: Main objective of this collaboration is to develop Fc engineered vaccines or therapeutics against human infectious diseases using… $52,961
Antagen Biosciences Inc. INTRODUCTION/BACKGROUND: Main objective of this collaboration isto develop fully human or chimeric IgA-IgG hybrid monoclonal antibodies (mAbs) against… $82,016
Icahn School Of Medicine At Mount Sinai INTRODUCTION/BACKGROUND: Dr. Sandra Isidean, located at the Naval Medical Research Command (NMRC), conducts research in the field of infectious diseases and… $854,751
Centivax, Inc. INTRODUCTION/BACKGROUND: Sepsis is an infection associated with organ injury that begins at the site of infection. The innate immune system recognizes… $183,694
Kericure Inc. INTRODUCTION/BACKGROUND: Dr. Le Breton will utilize the technical expertise of Dr. Greenhalgh at KeriCure to meet the objectives identified in the above… $42,306
Allvivo Vascular, Inc. INTRODUCTION/BACKGROUND: Antimicrobial peptides (AMPs) are a promising antimicrobial agent for the treatment of MDRO infections and the biofilms that they… $179,290
Georgia TECH Research Corp INTRODUCTION/BACKGROUND: Lytic bacteriophages (phage) are viruses that can specifically infect and lyse bacteria and are ubiquitous in the environment with… $305,402
Altrazeal Life Sciences Inc. An appreciable fraction of chronic refractory non-healing wounds harbor chronic infections (often polymicrobial and further complicated by biofilms)… $160,585
Loughborough University INTRODUCTION/BACKGROUND: Infected cutaneous ulcers are increasingly refractory to treatment given the 1). Advent of multidrug resistance to our current… $100,000
Cornell University Dr. McArt at Cornell University will performing a three-month pilot study in cows to test the immune response to a candidate enteric pathogen vaccine(s). Dr.… $148,616
Centivax, Inc. INTRODUCTION/BACKGROUND: Dr. Appavu Sundaram, located at Naval Medical Research Center (NMRC), Silver Spring, MD, conducts research in the field of viral… $60,118
Karolinska Institutet Dr. Appavu Sundaram, located at Naval Medical Research Center (NMRC), Silver Spring, MD, conducts research in the field of viral vaccines development and… $352,327
The Johns Hopkins University The Study PI�s located in the Enteric Diseases Department (EDD) in the Infectious Disease Directorate at the Naval Medical Research Center (NMRC)… $2,381,246
Wake Forest University Health Sciences INTRODUCTION/BACKGROUND: The main objective of this initiative is to develop and evaluate rapid and novel vaccine platforms and immunotherapeutics to prevent… $2,646,836
Immuron LIMITED The subaward study PI is the CEO of IMMURON, a biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibodies that target the human gut… $355,881
Show all 18

Quick answers

Who received award N626451920002?

N626451920002 was awarded to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. by Bureau of Medicine and Surgery (Department of the Navy) on September 27, 2019.

How much is award N626451920002 worth?

$82,338,342 has been obligated on N626451920002.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login